Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 11/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4293753 | 0.81 | PTGER4 (0.38) | PTGER4PTGER3USP2PTGER2P2RX7 | |
| SCHEMBL3675753 | 0.76 | PTGER4 (0.35) | PTGER4PTGER3USP2PTGER2P2RX7 | |
| SCHEMBL3682613 | 0.76 | PTGER4 (0.37) | PTGER4PTGER3USP2PTGER2TSHR | |
| SCHEMBL3676019 | 0.74 | PTGER4 (0.38) | PTGER4PTGER3PTGER2 | |
| SCHEMBL3680513 | 0.74 | GAA (0.38) | PTGER4PTGER3USP2TSHRALOX15 | |
| SCHEMBL4288018 | 0.74 | PTGER4 (0.58) | PTGER4PTGER3PTGER2 | |
| SCHEMBL4282353 | 0.74 | PTGER4 (0.58) | PTGER4PTGER3PTGER2 | |
| SCHEMBL4288000 | 0.74 | PTGER4 (0.58) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6703921 | 0.69 | PTGER4 (0.49) | PTGER4PTGER3PTGER2P2RX7KMT2A | |
| SCHEMBL6791024 | 0.63 | P2RX7 (0.41) | PTGER4PTGER3PTGER2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317013-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | BILLOT XAVIER (CA) | 2013-11-28 | — | — | US | claimed |
| US-20090258918-A1 | EP4 receptor agonist, compositions and methods thereof | BILLOT XAVIER | 2009-10-15 | — | — | US | claimed |
| US-20050239872-A1 | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma | MERCK FROSST CANADA LTD. (CA) | 2005-10-27 | — | — | US | claimed |
| US-20130317013-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | BILLOT XAVIER (CA) | 2013-11-28 | — | — | US | disclosed |
| US-20090258918-A1 | EP4 receptor agonist, compositions and methods thereof | BILLOT XAVIER | 2009-10-15 | — | — | US | disclosed |
| US-20050239872-A1 | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma | MERCK FROSST CANADA LTD. (CA) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239872-A1 | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma | PTGER1, PTGER4, PTGER2 | PTGER4 2/4885PTGER3 4/4885USP2 3873/4885 |
| US-20090258918-A1 | EP4 receptor agonist, compositions and methods thereof | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER3 3/4885USP2 3777/4885 |
| US-20130317013-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER3 3/4885USP2 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.